Century Therapeutics, Inc. (IPSC)
| Market Cap | 746.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -83.16M |
| Shares Out | 56.56M |
| EPS (ttm) | -4.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,941 |
| Open | 12.98 |
| Previous Close | 13.12 |
| Day's Range | 12.80 - 13.57 |
| 52-Week Range | 12.47 - 32.90 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 36.00 (+172.7%) |
| Earnings Date | n/a |
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD7...
Analyst Forecast
According to 4 analysts, the average rating for IPSC stock is "Buy." The 12-month stock price forecast is 36.00, which is an increase of 172.73% from the latest price.
News
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs...
Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...
Century Therapeutics Added to the NASDAQ Biotechnology Index
PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...
Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Pro...
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 -
Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
Lead program, CNTY-101 in relapsed/refractory non-Hodgkin's lymphoma, remains on track for IND filing in mid-2022
Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering
Collaboration enables Century to explore Outpace's protein solutions for cell therapy to enhance functionality of iPSC platform
Century Therapeutics Announces Its Addition to the Russell 2000® Index
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno...
Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221...
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purcha...
PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...
Century Therapeutics Announces Pricing of Initial Public Offering
PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today...